A new study from the American Diabetes Association journal Diabetes Care found that Type 1 diabetes patients who took Invokana (canagliflozin) alongside insulin therapy were more likely to experience diabetic ketoacidosis. Diabetic ketoacidosis is a severe and potentially fatal blood condition that develops when too many blood acids, or ketones, are present in the body.
Invokana, which is manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals, belongs to a ...
continue reading...
According to a Medscape article, the results of the first-ever Phase 2 study of sodium-glucose cotransporter-2 (SGLT2) inhibitor use in type 1 diabetes patients have been reported—and they may not be as reassuring as many had hoped. The data were presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting by Robert R. Henry, MD, chief of the Division of Endocrinology and Metabolism at the University ...
Cambridge News reports on a new study that suggests certain type 2 diabetes medications may in fact be doing the very thing they’re supposed to prevent. The study, published last week in the Journal of Biological Chemistry, says drugs belonging to the glucagon-like peptide-1 (GLP-1) agonist class, such as AstraZeneca’s Byetta, “may actually release sugar into the blood.” The findings are problematic, considering high blood sugar is ...
When most people hear an alarm, their first instinct is to determine if their lives are in jeopardy. When a fire alarm goes off, you quickly try to determine the extent and location of the fire. When the emergency broadcast system conducts a test you listen to find out if it is a test or if something grave requiring a responsive action.
It is troubling then that for as long as the ...
continue reading...Intarcia Therapeutics Inc. has released clinical research that, according to the company’s CEO, shows that their new diabetes pump will have “broad appeal in the market.” Intarcia, a private biotech firm from Boston, reported that their new implantable pump, called ITCA 650, performed better in glucose reduction and weight loss when compared to diabetes drugs currently on the market, including Merck’s Januvia.
According to an article in Bloomberg Business, the continue reading...
A recently published review found evidence that organized diet and exercise programs designed to prevent diabetes may truly be helpful in delaying or preventing the disease. The report was published in the Annals of Internal Medicine and reported by Reuters.
The findings of this study on diabetes prevention programs are positive and, hopefully, encourage those at risk for the disease to pursue lifestyle changes through prevention programs readily ...
continue reading...
